A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

• Status: Terminated
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Human Genome Sciences Inc.

Criteria

Inclusion Criteria:

• Confirmed relapsed/refractory lymphoid malignancies

• Previously treated with at least 2 therapeutic regimens

• ECOG performance < 2.

• Life expectancy of at least 3 months

• Adequate renal function

• Adequate hematologic status

• Adequate liver function

• Transfusion independent

Exclusion Criteria:

• Received other therapy (biological or drug) to treat cancer within 4 weeks prior to starting treatment with HGS1029 or who exhibit persistent clinical evidence of cancer treatment toxicity

• The use of systemic corticosteroids within 1 week of starting treatment with HGS1029

• Evidence of active bacterial, viral or fungal infection within 2 weeks before starting treatment with HGS1029

• Known HIV infection

• Positive for hepatitis B surface antigen or positive hepatitis C antibody

• Grade 2 or greater neuropathy

• Pregnant female or nursing mother

• Males or females who do not agree to use effective contraception during the study and through at least 30 days after the last dose of HGS1029